Innovative Medical Technology CathWorks specializes in advanced computational science to enhance coronary artery disease diagnostics, offering a unique FFR-guided PCI decision-making system that improves clinical outcomes and operational efficiency for healthcare providers.

Strategic Industry Recognition The company has been recognized as a finalist in the 2025 Octane High Tech Awards and has received high-profile partnerships with global medical device leaders like Medtronic, signaling strong industry validation and credibility.

Expanding Market Presence Recent participation in major industry events such as EuroPCR 2025 and the launch of the ALL-RISE Study demonstrate CathWorks' growing engagement in key clinical and commercial markets, creating opportunities for expanding customer base and adoption.

Robust Financial Backing With a substantial investment of $75 million and revenue estimates between $10 million and $25 million, CathWorks is financially positioned to scale sales efforts, invest in product development, and explore new market segments.

Potential for Partnership Expansion Existing collaborations with device distributors and a strategic partnership with Medtronic highlight opportunities to leverage these relationships for broader market penetration and increased sales of the FFRangio system across multiple regions and healthcare networks.